2025 United States Anti-Retroviral Drugs Revenue Opportunities Report
Description
The 2025 United States Anti-Retroviral Drugs Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. antiretroviral drugs market are Gilead Sciences, AbbVie, Johnson & Johnson, and Bristol-Myers Squibb. Gilead Sciences is a leading innovator in HIV treatment, recently gaining FDA approval for Yeztugo (lenacapavir), a twice-yearly injectable PrEP medication offering significant progress in HIV prevention. AbbVie is known for MAVYRET, a direct-acting antiviral therapy for hepatitis C, with recent label expansions approved by the FDA. Johnson & Johnson and Bristol-Myers Squibb are also key players contributing to the development and marketing of branded antiretroviral therapies in the U.S. market.
These companies dominate a market expected to reach approximately USD 21.94 billion by 2034 amid increasing viral disease prevalence and ongoing HIV/AIDS challenges in the U.S.. Their portfolios include a range of drug classes such as nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors, which form the backbone of combination antiretroviral therapies essential for viral suppression and management. Continuous advancements by these firms address both treatment and prevention, emphasizing improved efficacy and patient adherence through innovations like long-acting injectables.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. antiretroviral drugs market are Gilead Sciences, AbbVie, Johnson & Johnson, and Bristol-Myers Squibb. Gilead Sciences is a leading innovator in HIV treatment, recently gaining FDA approval for Yeztugo (lenacapavir), a twice-yearly injectable PrEP medication offering significant progress in HIV prevention. AbbVie is known for MAVYRET, a direct-acting antiviral therapy for hepatitis C, with recent label expansions approved by the FDA. Johnson & Johnson and Bristol-Myers Squibb are also key players contributing to the development and marketing of branded antiretroviral therapies in the U.S. market.
These companies dominate a market expected to reach approximately USD 21.94 billion by 2034 amid increasing viral disease prevalence and ongoing HIV/AIDS challenges in the U.S.. Their portfolios include a range of drug classes such as nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors, which form the backbone of combination antiretroviral therapies essential for viral suppression and management. Continuous advancements by these firms address both treatment and prevention, emphasizing improved efficacy and patient adherence through innovations like long-acting injectables.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
